‘The authors and societies envision this record serving as a wide guideline for the responsible deployment of these brand-new therapies for our patients and teams,’ stated John H. Calhoon, MD, Professor and Chair of Cardiothoracic Medical procedures at the University of Texas Health Science Center San review and Antonio Co-chair. ‘With this overview as a foundation, our societies will program future documents to handle suitable data collection and make use of, best practices, team composition, and additional definition of patient characteristics.’ Speaking with respect to the American Association for Thoracic Surgery, Marc R.and Allos Therapeutics, Inc. today announced they have entered into a definitive merger agreement under which the companies will combine within an all-stock merger with a total equity value of approximately $686 million. The deal is expected to result in annual cost benefits synergies of between $55 million and $60 million, nearly all which are anticipated to be recognized in the first fiscal yr after closing. Under the terms of the transaction, which has been accepted by the boards of directors of both ongoing companies, Allos stockholders will receive a set ratio of 0.1282 shares of AMAG common stock for every share of Allos common stock they own. Following consummation of the merger, AMAG stockholders will very own around 61 % of the combined business and Allos stockholders will very own around 39 % of the combined company.